Business
Assertio Reports First Quarter 2025 Financial Results
First Quarter Total Net Product Sales of $26.0 Million, In Line with 2025 Outlook Provides Update on Long-Term Business Strategy Designed to Create Sustainable Near-Term Growth and Increased Long-Term Value LAKE FOREST, Ill., May 12, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs, today reported financial results
About this update from Assertio Holdings, Inc.
[{"type":"image","alt":"Assertio Holdings, Inc.","displaySize":"","headline":null,"caption":"Assertio Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":258,"height":65,"url":"https://media.zenfs.com/en/globenewswire.com/da1bca653bc4f6a56d9f42c854c5ee83"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GWZkt7ZOPvh6mbIYky9FKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/da1bca653bc4f6a56d9f42c854c5ee83","width":258,"height":65}},"lazy":false},{"type":"text","content":"First Quarter Total Net Product Sales of $26.0 Million, In Line with 2025 Outlook","length":81,"tagName":"p"},{"type":"text","content":"Provides Update on Long-Term Business Strategy Designed to Create Sustainable Near-Term Growth and Increased Long-Term Value ","length":124,"tagName":"p"},{"type":"text","content":"LAKE FOREST, Ill., May 12, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs, today reported financial results for the first quarter ended March 31, 2025.","length":341,"tagName":"p"},{"type":"text","content":"Said Brendan O’Grady, Chief Executive Officer, “We have achieved substantial progress to date as we implement our business strategy designed to create sustainable near-term growth and increased long-term value as a specialty pharmaceutical company focused on commercial assets. As part of this strategy, Assertio’s 2025 transformation priorities include reducing legal exposure, simplifying our corporate structure and processes, prioritizing investment in growth assets, divesting declining or non-core assets, and using the strength of our balance sheet to close a strategic transaction.”","length":590,"tagName":"p"},{"type":"text","content":"Executing on these priorities through the first quarter, Assertio has:","length":70,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Settled multiple prior legal matters, including the previously disclosed DOJ False Claims Act qui tam lawsuit, the last remaining Glumetza antitrust action, Spectrum’s legacy Luo securities class action (subject to court approval), and obtained a dismissal of the Company’s Edwards securities class action, reducing f...